| Literature DB >> 35629411 |
Paolo Del Fiore1, Irene Russo1,2, Alessandro Dal Monico2, Jacopo Tartaglia2, Beatrice Ferrazzi3, Marcodomenico Mazza1, Francesco Cavallin4, Saveria Tropea1, Alessandra Buja5, Rocco Cappellesso6, Lorenzo Nicolè7,8, Vanna Chiarion-Sileni9, Chiara Menin10, Antonella Vecchiato1, Angelo Paolo Dei Tos6, Mauro Alaibac2, Simone Mocellin1,11.
Abstract
The incidence of cutaneous melanoma has been increasing in the last decades among the fair-skinned population. Despite its complex and multifactorial etiology, the exposure to ultraviolet radiation (UVR) is the most consistent modifiable risk factor for melanoma. Several factors influence the amount of UVR reaching the Earth's surface. Our study aimed to explore the relationship between melanoma and altitude in an area with mixed geographic morphology, such as the Veneto region (Italy). We included 2752 melanoma patients who were referred to our centers between 1998 and 2014. Demographics, histological and clinical data, and survival information were extracted from a prospectively maintained local database. Head/neck and acral melanoma were more common in patients from the hills and the mountains, while limb and trunk melanoma were more common in patients living in plain and coastal areas. Breslow thickness, ulceration and mitotic rate impaired with increased altitude. However, the geographical area of origin was not associated with overall or disease-free survival. The geographical area of origin of melanoma patients and the "coast-plain-hill gradient" could help to estimate the influence of different sun exposure and to explain the importance of vitamin D levels in skin-cancer control.Entities:
Keywords: altitude; coast-plain-hill gradient; cutaneous melanoma
Year: 2022 PMID: 35629411 PMCID: PMC9146073 DOI: 10.3390/life12050745
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Demographics and tumor characteristics according to the geographical area of residency of all patients.
| Hills (n = 56) | Coast (n = 262) | Mountains (n = 34) | Plain Area (n = 2400) | ||
|---|---|---|---|---|---|
| Age, years: | |||||
| Median (IQR) | 46 (39–63) | 53 (39–63) | 46 (38–64) | 51 (39–64) | 0.61 |
| Males: n (%) | 29 (51.8%) | 127 (48.5%) | 21 (61.8%) | 1133 (47.2%) | 0.34 |
| Primary site: n (%): | <0.0001 | ||||
| Hand and foot | 5 (8.9%) | 13 (5.0%) | 3 (8.8%) | 134 (5.6%) | |
| Head/neck | 17 (30.4%) | 23 (8.8%) | 4 (11.8%) | 140 (5.8%) | |
| Upper limb | 6 (10.7%) | 35 (13.4%) | 4 (11.8%) | 346 (14.4%) | |
| Trunk | 17 (30.4%) | 120 (45.8%) | 14 (41.2%) | 1161 (48.4%) | |
| Lower limb | 11 (19.6%) | 71 (27.0%) | 9 (26.4%) | 619 (25.8%) | |
| Breslow, mm: | <0.0001 | ||||
| Median (IQR) | 2.0 (1.1–4.4) | 0.7 (0.5–1.8) | 1.6 (0.5–2.3) | 0.7 (0.4–1.5) | |
| Data not available | 3 (5.3%) | 8 (3.0%) | 1 (2.9%) | 58 (2.4%) | |
| Ulceration, n (%): | 0.03 | ||||
| Absent | 33 (59.0%) | 206 (78.6%) | 27 (79.4%) | 1859 (77.4%) | |
| Present | 19 (33.9%) | 46 (17.6%) | 7 (20.6%) | 479 (20.0%) | |
| Data not available | 4 (7.1%) | 10 (3.8%) | - | 62 (2.6%) | |
| Mitoses per mm2: | <0.0001 | ||||
| Median (IQR) | 4 (2–8) | 1 (0–3) | 2 (0–3) | 1 (0–4) | |
| Data not available | 1 (1.7%) | 1 (0.4%) | - | 13 (0.5%) | |
| pTNM, n (%): | <0.0001 | ||||
| I | 23 (41.1%) | 175 (66.8%) | 18 (52.9%) | 1696 (70.7%) | |
| II | 21 (37.5%) | 48 (18.3%) | 8 (23.6%) | 334 (13.9%) | |
| III | 12 (21.4%) | 39 (14.9%) | 7 (20.6%) | 369 (15.4%) | |
| IV | 0 (0.0%) | 0 (0.0%) | 1 (2.9%) | 1 (0.0%) | |
| Subtype, n (%): | 0.09 | ||||
| ALM | 2 (3.6%) | 3 (1.1%) | 0 (0.0%) | 75 (3.1%) | |
| LMM | 2 (3.6%) | 5 (1.9%) | 0 (0.0%) | 32 (1.3%) | |
| NM | 13 (23.2%) | 44 (16.8%) | 6 (17.6%) | 355 (14.8%) | |
| SSM | 32 (57.1%) | 192 (73.3%) | 26 (76.5%) | 1813 (75.5%) | |
| Other | 5 (8.9%) | 11 (4.2%) | 2 (5.9%) | 78 (3.3%) | |
| Data not available | 2 (3.6%) | 7 (2.7%) | - | 47 (2.0%) |
ALM = acral lentiginous melanoma; LMM = lentigo maligna melanoma; NM = nodular melanoma; SSM = superficial spreading melanoma.
Demographics and tumor characteristics according to the geographical area of residency of referred patients.
| Hills (n = 56) | Coast (n = 262) | Mountains (n = 34) | Plain Area (n = 766) | ||
|---|---|---|---|---|---|
| Age, years: | |||||
| Median (IQR) | 46 (39–63) | 53 (39–63) | 46 (38–64) | 49 (38–62) | 0.43 |
| Males, n (%) | 29 (51.8%) | 127 (48.5%) | 21 (61.8%) | 357 (46.6%) | 0.32 |
| Primary site, n (%): | 0.005 | ||||
| Hand and foot | 5 (8.9%) | 13 (5.0%) | 3 (8.8%) | 58 (7.6%) | |
| Head/neck | 17 (30.4%) | 23 (8.8%) | 4 (11.8%) | 76 (9.9%) | |
| Upper limb | 6 (10.7%) | 35 (13.4%) | 4 (11.8%) | 187 (24.4%) | |
| Trunk | 17 (30.4%) | 120 (45.8%) | 14 (41.2%) | 336 (43.9%) | |
| Lower limb | 11 (19.6%) | 71 (27.0%) | 9 (26.4%) | 109 (14.2%) | |
| Breslow, mm: | <0.0001 | ||||
| Median (IQR) | 2.0 (1.1–4.4) | 0.7 (0.5–1.8) | 1.6 (0.5–2.3) | 1.0 (0.5–2.5) | |
| Data not available | 3 (5.3%) | 8 (3.0%) | 1 (2.9%) | 42 (5.4%) | |
| Ulceration, n (%): | 0.009 | ||||
| Absent | 33 (59.0%) | 206 (78.6%) | 27 (79.4%) | 539 (70.4%) | |
| Present | 19 (33.9%) | 46 (17.6%) | 7 (20.6%) | 199 (26.0%) | |
| Data not available | 4 (7.1%) | 10 (3.8%) | - | 28 (3.6%) | |
| Mitoses per mm2: | <0.0001 | ||||
| Median (IQR) | 4 (2–8) | 1 (0–3) | 2 (0–3) | 2 (0–4) | |
| Data not available | 1 (1.7%) | 1 (0.4%) | - | 9 (1.1%) | |
| pTNM, n (%): | <0.0001 | ||||
| I | 23 (41.1%) | 175 (66.8%) | 18 (52.9%) | 435 (56.8%) | |
| II | 21 (37.5%) | 48 (18.3%) | 8 (23.6%) | 153 (20.0%) | |
| III | 12 (21.4%) | 39 (14.9%) | 7 (20.6%) | 177 (23.1%) | |
| IV | 0 (0.0%) | 0 (0.0%) | 1 (2.9%) | 1 (0.1%) | |
| Subtype, n (%): | 0.25 | ||||
| ALM | 2 (3.6%) | 3 (1.1%) | 0 (0.0%) | 26 (3.4%) | |
| LMM | 2 (3.6%) | 5 (1.9%) | 0 (0.0%) | 14 (1.7%) | |
| NM | 13 (23.2%) | 44 (16.8%) | 6 (17.6%) | 165 (21.5%) | |
| SSM | 32 (57.1%) | 192 (73.3%) | 26 (76.5%) | 495 (64.6%) | |
| Other | 5 (8.9%) | 11 (4.2%) | 2 (5.9%) | 32 (4.2%) | |
| Data not available | 2 (3.6%) | 7 (2.7%) | - | 35 (4.6%) |
ALM = acral lentiginous melanoma; LMM = lentigo maligna melanoma; NM = nodular melanoma; SSM = superficial spreading melanoma.
Figure 1Disease-specific survival in all patients.
Figure 2Disease-specific survival in referred patients.
Multivariable analysis of predictors of disease-specific survival.
| All Patients | Referred Patients | |||
|---|---|---|---|---|
| Hazard Ratio (95% Confidence Interval) | Hazard Ratio (95% Confidence Interval) | |||
| Geographical area: | ||||
| Hills | 0.95 (0.52 to 1.72) | 0.86 | 1.23 (0.66 to 2.29) | 0.51 |
| Coast | 1.09 (0.73 to 1.62) | 0.68 | 1.09 (0.73 to 1.62) | 0.89 |
| Mountains | 0.65 (0.21 to 2.04) | 0.46 | 0.65 (0.21 to 2.04) | 0.54 |
| Plain area | Reference | Reference | ||
| Primary site: | ||||
| Head/neck | 1.46 (0.98 to 2.17) | 0.06 | 1.68 (0.38 to 1.19) | 0.18 |
| Trunk | Reference | Reference | ||
| Limbs | 0.95 (0.74 to 1.22) | 0.71 | 0.75 (0.52 to 1.07) | 0.11 |
| Breslow, mm | 1.07 (1.05 to 1.09) | <0.0001 | 1.13 (1.10 to 1.16) | <0.0001 |
| Ulceration: | 0.0006 | |||
| Absent | Reference | Reference | ||
| Present | 2.96 (2.25 to 3.89) | <0.0001 | 1.95 (1.33 to 2.85) | |
| Mitoses per mm2 | 1.08 (1.06 to 1.09) | <0.0001 | 1.06 (1.02 to 1.09) | 0.0006 |
| pTNM: | ||||
| I-II | Reference | Reference | ||
| III-IV | 2.68 (2.06 to 3.48) | <0.0001 | 2.39 (1.65 to 3.46) | <0.0001 |
Figure 3Disease-free survival in all patients.
Figure 4Disease-free survival in referred patients.
Multivariable analysis of predictors of disease-free survival.
| All Patients | Referred Patients | |||
|---|---|---|---|---|
| Hazard Ratio (95% Confidence Interval) | Hazard Ratio (95% Confidence Interval) | |||
| Geographical area: | ||||
| Hills | 0.97 (0.56 to 1.68) | 0.91 | 0.98 (0.55 to 1.73) | 0.94 |
| Coast | 1.12 (0.78 to 1.60) | 0.54 | 0.95 (0.65 to 1.39) | 0.8 |
| Mountains | 0.68 (0.25 to 1.84) | 0.45 | 0.62 (0.23 to 1.68) | 0.35 |
| Plain area | Reference | Reference | ||
| Primary site: | ||||
| Head/neck | 2.03 (1.42 to 2.90) | <0.0001 | 1.56 (0.99 to 2.47) | 0.05 |
| Trunk | Reference | Reference | ||
| Limbs | 1.22 (0.97 to 1.53) | 0.09 | 1.23 (0.89 to 1.70) | 0.21 |
| Breslow, mm | 1.06 (1.04 to 1.08) | <0.0001 | 1.10 (1.07 to 1.13) | <0.0001 |
| Ulceration: | 0.004 | |||
| Absent | Reference | Reference | ||
| Present | 2.28 (1.78 to 2.91) | <0.0001 | 1.63 (1.17 to 2.26) | |
| Mitoses per mm2 | 1.07 (1.05 to 1.08) | <0.0001 | 1.06 (1.03 to 1.09) | <0.0001 |
| pTNM: | ||||
| I-II | Reference | Reference | ||
| III-IV | 3.50 (2.75 to 4.45) | <0.0001 | 3.20 (2.32 to 4.1) | <0.0001 |